Anna van Muyden is a clinical development leader with 10 years of experience in the field of hemato-oncology and ATMPs, and is passionate about bringing innovative treatments to patients. In 2019, she joined the Leiden-based biotech start-up CellPoint B.V. as the first hire and Head of Clinical Development, leading the company’s clinical CAR-T programs in hematology. After the successful acquisition by the Dutch-Belgian biotech company Galapagos in 2022, she has continued her career as Head of Clinical Science Oncology. Anna holds a BSc in Biomedical Sciences and an MSc in Science and Business Management from Utrecht University. Previous positions include running clinical trial operations in UMC Utrecht and leading a first-in-human program in the Dutch cancer immunotherapies company Gadeta.